<DOC>
	<DOCNO>NCT02223507</DOCNO>
	<brief_summary>The objective present study obtain information safety , tolerability pharmacokinetics BIIR 561 CL continuous intravenous administration two increase dos healthy elderly volunteer , follow infusion schema load dose ( 1 hour ) maintenance dose ( 5 hour )</brief_summary>
	<brief_title>Single Dose Followed Maintenance Dose Tolerance Study BIIR 561 CL Healthy Elderly Male Female Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy male female volunteer Age &gt; = 60 year Broca index 25 % +25 % Written inform consent prior admission study Any finding medical examination ( include blood pressure , pulse rate Electrocardiogram ( ECG ) ) deviate normal clinical relevance Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder ( exclusion : substitution therapy regard thyroid gland and/or ovary ) Diseases central nervous system ( CNS ) ( epilepsy ) psychiatric disorder neurological disorder medical history diseases disorder History orthostatic hypotension , faint spell blackouts Chronic relevant acute infection Allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator Intake drug long halflife ( &gt; 24 hour ) within least one month less ten halflives respective drug enrolment study Intake drug might influence result trial ( &lt; = one week prior administration trial ) Participation another trial investigational drug ( &lt; = two month prior administration trial Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability refrain smoke trial day Alcohol abuse ( &gt; 30g/day male , &gt; 24 g female ) Drug abuse Blood donation ( &gt; = 100 ml within four week prior administration trial ) Excessive physical activity ( within last week study ) Any laboratory value outside reference range clinical relevance</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>